Skip to main content

CORRECTION article

Front. Oncol., 12 January 2023
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1061604

Corrigendum: H3K27M mutation doesn’t mean worse prognosis in old patients

This article is a correction to:

  1. H3K27M Mutation Doesn’t Mean Worse Prognosis in Old Patients

    1. Read original article
Xiao Mu HuXiao Mu Hu1Xiao yu Nie&#x;Xiao yu Nie2†Kai lun Xu&#x;Kai lun Xu3†Yin WangYin Wang1Feng TangFeng Tang1Zun guo Du*Zun guo Du1*Ji Xiong*Ji Xiong1*
  • 1Huashan Hospital, Fudan University, Shanghai, China
  • 2Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 3Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

A Corrigendum on
H3K27M mutation doesn’t mean worse prognosis in old patients

By Hu XM, Nie Xy, Xu Kl, Wang Y, Tang F, Du Zg and Xiong J (2022) 12:912166. doi: 10.3389/fonc.2022.912166

In the published article, there was an error. There was a data error in the abstract.

A correction has been made to the Abstract, Results, Paragraph 1. This sentence previously stated:

“The median overall survival of H3K27M-mutant gliomas and the 80 H3K27M wild-type gliomas were both 12 months”.

The corrected sentence appears below:

“The median overall survival of H3K27M-mutant gliomas and the 70 H3K27M wild-type gliomas were both 17 months”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: midline glioma, H3K27M, clinicopathological study, prognosis, age

Citation: Hu XM, Nie Xy, Xu Kl, Wang Y, Tang F, Du Zg and Xiong J (2023) Corrigendum: H3K27M mutation doesn’t mean worse prognosis in old patients. Front. Oncol. 12:1061604. doi: 10.3389/fonc.2022.1061604

Received: 04 October 2022; Accepted: 30 December 2022;
Published: 12 January 2023.

Edited and Reviewed by:

Pankaj Pathak, National Institutes of Health (NIH), United States

Copyright © 2023 Hu, Nie, Xu, Wang, Tang, Du and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zun guo Du, duzunguo@sina.com.cn; Ji Xiong, dabenx@163.com

†These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.